# Testing the performance of polygenic scores for multiple traits to explain cerebral palsy in two independent cohorts

**Authors:** Jodi T. Thomas, Alexander S.F. Berry, Matthew T. Oetjens, Jesia G. Berry, Alastair H. MacLennan, Scott D. Gordon, Andrew T. Hale, Catherine M. Olsen, David C. Whiteman, Rebecca I. Torene, David H. Ledbetter, Nicholas G. Martin, Clare L. van Eyk, Jozef Gecz, Scott M. Myers, Brittany L. Mitchell, Mark A. Corbett

PMC · DOI: 10.1016/j.ebiom.2026.106208 · eBioMedicine · 2026-03-14

## TL;DR

This study shows that common genetic variants contribute to cerebral palsy risk and share genetic links with environmental factors like birth weight and stroke.

## Contribution

Demonstrates measurable polygenic contribution to CP and shared genetic influences with environmental risk factors using two independent cohorts.

## Key findings

- Combined polygenic scores explained 1.3% of CP liability in the Australian cohort and 0.78% in MyCode.
- Polygenic scores for birth weight, gestational duration, and stroke showed modest predictive performance.
- Results were consistent across cohorts and within monogenic CP subgroups.

## Abstract

Cerebral palsy (CP) is a complex neurodevelopmental disorder with both environmental and genetic contributors. Rare genetic variants explain a substantial proportion of CP, but the contribution of common variants remains unclear. We evaluated whether polygenic scores for CP and related traits explain the aetiology of CP.

We analysed two independent target cohorts: a case–control cohort including people with a confirmed clinical diagnosis of CP from the Australian CP Biobank and population-based controls; and MyCode, a United States healthcare cohort with CP status identified by electronic health records. Only participants of European genetic ancestry were included. CP polygenic scores were constructed using a publicly available discovery genome-wide association meta-analysis of Finnish and UK cohorts (ncases = 624, ncontrols = 495,687) and applied to the target cohorts for out-of-sample prediction. Additional polygenic scores were generated from publicly available genome-wide association studies for seven CP-related traits. Predictive performance was assessed using logistic regression, area under the receiver operating characteristic curve, and variance in CP liability explained.

The Australian cohort included 525 cases and 20,410 controls, and MyCode 322 cases and 1610 age-matched controls. The combined model of all eight polygenic scores significantly discriminated CP status, explaining 1·3% of CP liability in the Australian cohort (90% CI lower bound 0·82%, padj<0·0001), and 0·78% in MyCode (90% CI lower bound 0·35%, padj<0·0001). CP-specific polygenic scores demonstrated minimal predictive signal, likely reflecting limited GWAS power. Polygenic scores for known CP predisposing factors (birth weight, gestational duration, stroke) showed modest predictive performance, with some cohort differences. Results were similar when the Australian cohort was stratified by monogenic CP diagnosis.

Our findings demonstrate a measurable polygenic contribution to CP and shared genetic influences with predisposing factors, including those traditionally considered environmental, and comorbidities. Common variants appear to contribute broadly to CP susceptibility, highlighting a multifactorial landscape relevant for earlier diagnosis and intervention.

Cerebral Palsy Alliance Research Foundation, NICHD, NHMRC, MRFF, QIMR Berghofer.

## Linked entities

- **Diseases:** cerebral palsy (MONDO:0006497), stroke (MONDO:0005098)

## Full-text entities

- **Genes:** NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, MBL2 (mannose binding lectin 2) [NCBI Gene 4153] {aka COLEC1, HSMBPC, MBL, MBL2D, MBP, MBP-C}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, CP (ceruloplasmin) [NCBI Gene 1356] {aka AB073614, CP-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, COL4A2 (collagen type IV alpha 2 chain) [NCBI Gene 1284] {aka BSVD2, BSVD2A, BSVD2B, ICH, POREN2}, MTHFR (methylenetetrahydrofolate reductase) [NCBI Gene 4524], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** maldevelopment of the (MESH:C538059), foetal growth restriction (MESH:D005317), thrombophilia (MESH:D019851), familial monogenic epilepsy (MESH:D000073376), gestational diabetes (MESH:D016640), inflammation (MESH:D007249), seizure (MESH:D012640), viral infection (MESH:D014777), ASD (MESH:D000067877), spastic hemiplegia (MESH:D006429), Melanoma (MESH:D008545), prematurity (MESH:C536271), CP (MESH:D002547), brain (MESH:D001927), vision impairments (MESH:D014786), physical impairments (MESH:D059445), speech impairments (MESH:D013064), Cancer (MESH:D009369), fidgety movements (MESH:D009069), intellectual disability (MESH:D008607), intellectual impairment (MESH:C565406), birth (MESH:D000014), periventricular leukomalacia (MESH:D007969), Stroke (MESH:D020521), skin cancer (MESH:D012878), ischaemic stroke (MESH:D002544), developmental delay (MESH:D002658), infection (MESH:D007239), epilepsy (MESH:D004827), autism (MESH:D001321)
- **Chemicals:** dopamine (MESH:D004298), BLM (MESH:D001761), MTO (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs1800795

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13000708/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13000708/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC13000708/full.md

---
Source: https://tomesphere.com/paper/PMC13000708